To the full analysis
Buyback calculator for Aurinia Pharmaceuticals
Aurinia Pharmaceuticals stock: key metrics
AUPHAurinia Pharmaceuticals had an operating margin of 37.1% and a return on invested capital (ROIC) of 58.9% in fiscal 2025.
Margins show how much of revenue is left over, returns on capital how hard the invested money works.
Daily figure as of 13 Nov 2026
Margins
- Gross margin
- Operating margin
- Net margin
Figures as a table
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| 2006 | 83.0% | −685.7% | −648.7% |
| 2007 | 55.0% | −1,543.0% | −1,448.7% |
| 2008 | 45.4% | −422.0% | −409.7% |
| 2009 | 85.8% | −247.9% | −187.5% |
| 2010 | 98.5% | −147.5% | −107.0% |
| 2011 | 80.0% | −694.2% | −259.6% |
| 2012 | 99.2% | −88.8% | −158.1% |
| 2013 | 99.9% | −580.4% | −268.4% |
| 2014 | 86.7% | −6,216.5% | −5,988.1% |
| 2015 | 94.9% | −10,034.0% | −7,917.9% |
| 2016 | 97.7% | −13,187.3% | −13,465.3% |
| 2017 | 99.8% | −11,205.5% | −16,855.2% |
| 2018 | −8,837.8% | −12,129.2% | −13,848.8% |
| 2019 | 100.0% | −28,598.4% | −27,794.0% |
| 2020 | 100.0% | −208.1% | −204.9% |
| 2021 | 97.6% | −396.3% | −396.8% |
| 2022 | 95.8% | −83.2% | −80.7% |
| 2023 | 91.9% | −52.2% | −44.5% |
| 2024 | 88.0% | −2.0% | 2.4% |
| 2025 | 88.5% | 37.1% | 101.5% |
Returns on capital
- ROE
- ROIC
- ROA
Figures as a table
| Year | ROE | ROIC | ROA |
|---|---|---|---|
| 2006 | −100.0% | −75.0% | −74.6% |
| 2007 | −100.0% | −98.3% | −79.3% |
| 2008 | −100.0% | −47.2% | −59.6% |
| 2009 | −100.0% | −55.5% | −79.6% |
| 2010 | −57.7% | −52.3% | −35.6% |
| 2011 | −37.5% | −48.0% | −16.8% |
| 2012 | 200.0% | −59.8% | −100.0% |
| 2013 | −19.1% | −82.6% | −11.0% |
| 2014 | −36.9% | −40.2% | −31.8% |
| 2015 | −93.2% | −46.9% | −55.4% |
| 2016 | −64.8% | −45.6% | −40.9% |
| 2017 | −42.7% | −32.2% | −37.3% |
| 2018 | −57.0% | −27.7% | −44.0% |
| 2019 | −29.6% | −31.8% | −27.3% |
| 2020 | −25.2% | −22.1% | −22.1% |
| 2021 | −37.8% | −30.6% | −33.3% |
| 2022 | −26.7% | −19.0% | −23.0% |
| 2023 | −20.6% | −97.1% | −14.2% |
| 2024 | 1.5% | −3.2% | 1.0% |
| 2025 | 49.4% | 58.9% | 38.2% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral since 12 Nov 2026, previously Strong
- Valuation signal Undervalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.